Amniotic Mesenchymal Stem Cells Mitigate Osteoarthritis Progression in a Synovial Macrophage-mediated in Vitro Explant Coculture Model
Overview
Biotechnology
Authors
Affiliations
Osteoarthritis (OA) is a disease of the synovial joint marked by chronic, low-grade inflammation leading to cartilage destruction. Regenerative medicine strategies for mitigating OA progression and/or promoting cartilage regeneration must be assessed using models that mimic the hallmarks of OA. More specifically, these models should maintain synovial macrophage phenotype in their native micro-environment. Herein, an in vitro coculture model of patient-matched human OA cartilage and synovium was assessed for viability, macrophage phenotype, and progressive cartilage destruction in the presence of an inflammatory milieu. Additionally, the influence of synovial macrophages and their polarization within the model was defined using depletion studies. Finally, the model was used to compare the ability of human amniotic stem cells (hAMSCs) and human adipose stem cells (hADSCs) to mitigate OA progression. OA cocultures demonstrated progressive and significant reductions in chondrocyte viability and cartilage glycosaminoglycan content within a proinflammatory environment. Selective depletion of synovial macrophages resulted in significant decreases in M1:M2 percentage ratio yielding significant reductions in concentrations of interleukin-1 beta, matrix metalloproteinase-13 and attenuation of cartilage damage. Finally, hAMSCs were found to be more chondroprotective versus hADSCs as indicated by significantly improved OA chondrocyte viability (89.8 ± 2.4% vs. 58.4 ± 2.4%) and cartilage glycosaminoglycan content (499.0 ± 101.9 μg/mg dry weight vs. 155.0 ± 26.3 μg/mg dry weight) and were more effective at shifting OA synovial macrophage M1:M2 ratio (1.3:1 vs. 5:1), respectively. Taken together, the coculture model mimics salient features of OA, including macrophage-mediated cartilage destruction that was effectively abrogated by hAMSCs but not hADSCs.
Development of a macrophage polarization-modulating therapeutic agent for osteoarthritis treatment.
Wu L, Cao X, Shen B J Orthop Surg Res. 2025; 20(1):279.
PMID: 40082923 PMC: 11908040. DOI: 10.1186/s13018-025-05679-2.
Exosome Source Matters: A Comprehensive Review from the Perspective of Diverse Cellular Origins.
Chen Y, Qi W, Wang Z, Niu F Pharmaceutics. 2025; 17(2).
PMID: 40006514 PMC: 11858990. DOI: 10.3390/pharmaceutics17020147.
Ragni E, Perucca Orfei C, Papait A, de Girolamo L Extracell Vesicles Circ Nucl Acids. 2024; 2(3):202-221.
PMID: 39697592 PMC: 11648501. DOI: 10.20517/evcna.2021.11.
Macrophage Polarization in the Osteoarthritis Pathogenesis and Treatment.
Zou X, Xu H, Qian W Orthop Surg. 2024; 17(1):22-35.
PMID: 39638774 PMC: 11735378. DOI: 10.1111/os.14302.
Innate Immunity and Synovitis: Key Players in Osteoarthritis Progression.
Panichi V, Costantini S, Grasso M, Arciola C, Dolzani P Int J Mol Sci. 2024; 25(22).
PMID: 39596150 PMC: 11594236. DOI: 10.3390/ijms252212082.